• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Solesence Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    7/31/25 4:32:54 PM ET
    $SLSN
    Package Goods/Cosmetics
    Consumer Discretionary
    Get the next $SLSN alert in real time by email
    Form 8-K
    False000088310700008831072025-07-312025-07-31iso4217:USDxbrli:sharesiso4217:USDxbrli:shares
     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

    _________________

    FORM 8-K

    _________________

    CURRENT REPORT

    Pursuant to Section 13 or 15(d)
    of the Securities Exchange Act of 1934

    Date of Report (Date of earliest event reported):  July 31, 2025

    _______________________________

    SOLESENCE, INC.

    (Exact name of registrant as specified in its charter)

    _______________________________

    Delaware000-2233336-3687863
    (State or Other Jurisdiction of Incorporation)(Commission File Number)(I.R.S. Employer Identification No.)

    1319 Marquette Drive

    Romeoville, Illinois 60446

    (Address of Principal Executive Offices) (Zip Code)

    (630) 771-6708

    (Registrant's telephone number, including area code)

     

    (Former name or former address, if changed since last report)

    _______________________________

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

    ☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
    ☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
    ☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
    ☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

    Securities registered pursuant to Section 12(b) of the Act:

    Title of each classTrading Symbol(s)Name of each exchange on which registered
    Common Stock, $0.01 par value per shareSLSNThe NASDAQ Capital Market

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

    Emerging growth company ☐

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

     
     
    Item 2.02. Results of Operations and Financial Condition.

     

    On July 31, 2025, the Registrant issued a press release, a copy of which is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

     

    Item 9.01. Financial Statements and Exhibits.
       
    99.1 Press Release dated July 31, 2025
    104 Cover Page Interactive Data File (embedded within the Inline XBRL document)

     

     

     
     

    SIGNATURE

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     SOLESENCE, INC.
       
      
    Date: July 31, 2025By: /s/ Jess Jankowski        
      Jess Jankowski
      Chief Executive Officer
      

     

     

    Get the next $SLSN alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $SLSN

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $SLSN
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Whitmore Bradford T bought $28,093,800 worth of shares (6,689,000 units at $4.20) and sold $28,093,800 worth of shares (6,689,000 units at $4.20) (SEC Form 4)

    4 - SOLESENCE, INC. (0000883107) (Issuer)

    6/2/25 4:01:15 PM ET
    $SLSN
    Package Goods/Cosmetics
    Consumer Discretionary

    $SLSN
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    $SLSN
    SEC Filings

    View All

    $SLSN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Solésence Announces Key Leadership Appointments to Drive Future Innovation and Growth

    ROMEOVILLE, Ill., Sept. 03, 2025 (GLOBE NEWSWIRE) -- Solésence, Inc. (NASDAQ:SLSN), a leader in scientifically-driven health care solutions across beauty and life science categories, today announced strategic changes to its executive leadership. Kevin Cureton, a driving force behind the company's expansion and innovation, will assume the role of President and Chief Executive Officer. Laura Riffner has been appointed Chief Financial Officer, bringing decades of financial expertise in enhancing operational excellence and efficiency. Jess Jankowski, who has been at the helm of the company as Chief Executive Officer since 2009, will serve as Board Advisor until his retirement from the company

    9/3/25 8:00:00 AM ET
    $SLSN
    Package Goods/Cosmetics
    Consumer Discretionary

    Solésence Reports Second Quarter 2025 Financial Results

    ROMEOVILLE, Ill., July 31, 2025 (GLOBE NEWSWIRE) -- Solésence, Inc. (NASDAQ:SLSN), a leader in scientifically-driven health care solutions across beauty and life science categories, today announced financial results for the second quarter ended June 30, 2025.    Recent Highlights and Accomplishments Joined broad-market Russell 3000® and small-cap Russell 2000® IndexesAmended loan agreements to fuel growth initiatives "During our seasonally highest-performing quarter, we're pleased with the effectiveness of our commercial execution and the consistent, on-time delivery of products to our partners," said Jess Jankowski, President and Chief Executive Officer of Solésence. "Innovation

    7/31/25 4:01:00 PM ET
    $SLSN
    Package Goods/Cosmetics
    Consumer Discretionary

    Solésence To Report Second Quarter 2025 Financial Results and Host a Conference Call

    ROMEOVILLE, Ill., July 24, 2025 (GLOBE NEWSWIRE) -- Solésence, Inc. (NASDAQ:SLSN), a leader in scientifically-driven health care solutions across beauty and life science categories, today announced that the Company will report results for the second quarter of 2025 after the market close on Thursday, July 31, 2025, and host a conference call and webcast on the same date. Second Quarter 2025 Conference Call Details Date / Time: Thursday, July 31, 2025 - 4:00 p.m. CDT, 5:00 p.m. EDT Speakers: Jess Jankowski, President & CEO, and Kevin Cureton, Chief Operating Officer Webcast Link: https://edge.media-server.com/mmc/p/7n5uumgk Dial-In Link: https://register-conf.media-server.com/register/

    7/24/25 8:00:00 AM ET
    $SLSN
    Package Goods/Cosmetics
    Consumer Discretionary

    Solesence Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Leadership Update, Financial Statements and Exhibits

    8-K - SOLESENCE, INC. (0000883107) (Filer)

    9/4/25 7:05:23 AM ET
    $SLSN
    Package Goods/Cosmetics
    Consumer Discretionary

    Solesence Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

    8-K - SOLESENCE, INC. (0000883107) (Filer)

    8/29/25 5:11:40 PM ET
    $SLSN
    Package Goods/Cosmetics
    Consumer Discretionary

    SEC Form 10-Q filed by Solesence Inc.

    10-Q - SOLESENCE, INC. (0000883107) (Filer)

    8/14/25 4:30:18 PM ET
    $SLSN
    Package Goods/Cosmetics
    Consumer Discretionary

    SEC Form 3 filed by new insider Riffner Laura C

    3 - SOLESENCE, INC. (0000883107) (Issuer)

    10/6/25 10:07:15 AM ET
    $SLSN
    Package Goods/Cosmetics
    Consumer Discretionary

    Chief Operating Officer Cureton Kevin exercised 43,500 shares at a strike of $0.42 and sold $166,051 worth of shares (43,500 units at $3.82) (SEC Form 4)

    4 - SOLESENCE, INC. (0000883107) (Issuer)

    6/6/25 7:00:04 PM ET
    $SLSN
    Package Goods/Cosmetics
    Consumer Discretionary

    Large owner Whitmore Bradford T bought $28,093,800 worth of shares (6,689,000 units at $4.20) and sold $28,093,800 worth of shares (6,689,000 units at $4.20) (SEC Form 4)

    4 - SOLESENCE, INC. (0000883107) (Issuer)

    6/2/25 4:01:15 PM ET
    $SLSN
    Package Goods/Cosmetics
    Consumer Discretionary

    $SLSN
    Leadership Updates

    Live Leadership Updates

    View All

    Solésence Announces Key Leadership Appointments to Drive Future Innovation and Growth

    ROMEOVILLE, Ill., Sept. 03, 2025 (GLOBE NEWSWIRE) -- Solésence, Inc. (NASDAQ:SLSN), a leader in scientifically-driven health care solutions across beauty and life science categories, today announced strategic changes to its executive leadership. Kevin Cureton, a driving force behind the company's expansion and innovation, will assume the role of President and Chief Executive Officer. Laura Riffner has been appointed Chief Financial Officer, bringing decades of financial expertise in enhancing operational excellence and efficiency. Jess Jankowski, who has been at the helm of the company as Chief Executive Officer since 2009, will serve as Board Advisor until his retirement from the company

    9/3/25 8:00:00 AM ET
    $SLSN
    Package Goods/Cosmetics
    Consumer Discretionary

    Solésence to Join Russell 3000® and Russell 2000® Indexes

    ROMEOVILLE, Ill., June 24, 2025 (GLOBE NEWSWIRE) -- Solésence, Inc. (NASDAQ:SLSN), a leader in scientifically-driven health care solutions across beauty and life science categories, today announced that it will be added as a member of the broad-market Russell 3000® and small-cap Russell 2000® Indexes, effective after the U.S. market opens on June 30, as part of the 2025 Russell indexes reconstitution. The annual reconstitution of the Russell US indexes captures the 4,000 largest US stocks as of April 30, ranking them by total market capitalization. Membership in the Russell 3000® Index, which remains in place for one year, means automatic inclusion in the large-cap Russell 1000® Index or

    6/24/25 8:00:00 AM ET
    $SLSN
    Package Goods/Cosmetics
    Consumer Discretionary

    $SLSN
    Financials

    Live finance-specific insights

    View All

    Solésence Reports Second Quarter 2025 Financial Results

    ROMEOVILLE, Ill., July 31, 2025 (GLOBE NEWSWIRE) -- Solésence, Inc. (NASDAQ:SLSN), a leader in scientifically-driven health care solutions across beauty and life science categories, today announced financial results for the second quarter ended June 30, 2025.    Recent Highlights and Accomplishments Joined broad-market Russell 3000® and small-cap Russell 2000® IndexesAmended loan agreements to fuel growth initiatives "During our seasonally highest-performing quarter, we're pleased with the effectiveness of our commercial execution and the consistent, on-time delivery of products to our partners," said Jess Jankowski, President and Chief Executive Officer of Solésence. "Innovation

    7/31/25 4:01:00 PM ET
    $SLSN
    Package Goods/Cosmetics
    Consumer Discretionary

    Solésence To Report Second Quarter 2025 Financial Results and Host a Conference Call

    ROMEOVILLE, Ill., July 24, 2025 (GLOBE NEWSWIRE) -- Solésence, Inc. (NASDAQ:SLSN), a leader in scientifically-driven health care solutions across beauty and life science categories, today announced that the Company will report results for the second quarter of 2025 after the market close on Thursday, July 31, 2025, and host a conference call and webcast on the same date. Second Quarter 2025 Conference Call Details Date / Time: Thursday, July 31, 2025 - 4:00 p.m. CDT, 5:00 p.m. EDT Speakers: Jess Jankowski, President & CEO, and Kevin Cureton, Chief Operating Officer Webcast Link: https://edge.media-server.com/mmc/p/7n5uumgk Dial-In Link: https://register-conf.media-server.com/register/

    7/24/25 8:00:00 AM ET
    $SLSN
    Package Goods/Cosmetics
    Consumer Discretionary

    Solésence Reports Record First Quarter 2025 Financial Results

    First quarter revenue increased 48% to a record $14.6 million ROMEOVILLE, Ill., May 05, 2025 (GLOBE NEWSWIRE) -- Solésence, Inc. (NASDAQ:SLSN), a leader in scientifically-driven health care solutions across beauty and life science categories, today announced financial results for the first quarter ended March 31, 2025.    Recent Highlights and Accomplishments Uplisted to Nasdaq under the ticker "SLSN" supporting the Company's increased visibility with the investment communityAchieved record revenue and unit volume shipments in the first quarter 2025 "We kicked off 2025 with record revenue, fueled by strong sales across our suite of consumer products," said Jess Jankowski, President and

    5/5/25 4:01:00 PM ET
    $SLSN
    Package Goods/Cosmetics
    Consumer Discretionary